Dermatomyositis

Seminars in Cutaneous Medicine and Surgery

Volumn 20, Issue 1, 2001, Pages 38-45

  Caro, I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PREDNISONE;

AUTOIMMUNE DISEASE; CALCINOSIS; CLINICAL FEATURE; DERMATOMYOSITIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; GENETIC LINKAGE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PATHOGENESIS; REVIEW; VASCULAR DISEASE;

EID: 0035073032     PISSN: 10855629     EISSN: None     Source Type: Journal    
DOI: 10.1053/sder.2001.23095     Document Type: Review

References (64)

1. A classification of polymyositis and dermatomyositis
2. History and classification of polymyositis and dermatomyositis
3. Association of inflammatory myopathies with other connective tissue disorders and malignancies
4. Dermatomyositis
5. Dermatomyositis (systemic angiopathy) of childhood
6. Polymyositis and dermatomyositis
7. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis
8. Incidence of polymyositis-dermatomyositis: A 20-year study of hospital diagnosed cases in Allegheny County, PA 1963-1982
9. Dermatomyositis and polymyositis
10. The incidence of juvenile dermatomyositis: Results from the NIAMS JDM research registry
11. New-onset juvenile dermatomyositis: Comparisons with a healthy cohort and children with juvenile rheumatoid arthritis
12. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue disease
13. Is there an association between injectable collagen and polymyositis/dermatomyositis?
14. Familial dermatomyositis
15. Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy
16. Infection and molecular mimicry in autoimmune diseases of childhood
17. Lack of detection of enteroviral RNA or bacterial DNA in magnetic resonance imaging-directed muscle biopsies from twenty children with active untreated juvenile dermatomyositis
18. Humoral immunity in polymyositis/dermatomyositis
19. Analysis of the Mi-2 autoantigen of dermatomyositis
20. Immune manifestations of inflammatory muscle disease
21. Cellular immunity in polymyositis/dermatomyositis
22. Strength in polymyositis and dermatomyositis: Best outcome in patients treated early
23. A dermatologist's view of polymyositis/dermatomyositis
24. Dermatomyositis
25. Cutaneous photosensitivity in dermatomyositis
26. Scalp involvement in dermatomyositis. Often overlooked or misdiagnosed
27. A cutaneous lesion associated with myositis
28. Clinical and histological features of 'mechanic's hands' in a patient with antibodies to Jo-1 - A case report
29. Panniculitis in juvenile dermatomyositis
30. Vesico-bullous dermatomyositis
31. Hypertrichosis in juvenile dermatomyositis
32. "Centripetal flagellate erythema": A cutaneous manifestation associated with dermatomyositis
33. The seborrheic pattern of dermatomyositis
34. Gingival telangiectases: An underappreciated physical sign of juvenile dermatomyositis
35. Cutaneous changes of dermatomyositis in patients with normal muscle enzymes: Dermatomyositis sine myositis
36. Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids
37. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis
38. Pulmonary involvement in polymyositis and dermatomyositis
39. Beware of the heart: The multiple picture of cardiac involvement in myositis
40. Skin and bones II
41. Computer-assisted analysis of 153 patients with polymyositis and dermatomyositis
42. Relationship of cancer to inflammatory muscle diseases. Dermatomyositis, polymyositis and inclusion body myositis
43. Ovarian malignancy in patients with dermatomyositis and polymyositis: A retrospective analysis of fourteen cases
44. Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study
45. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark
46. Elevated cancer incidence in patients with dermatomyositis: A population based study
47. Special considerations concerning the cutaneous manifestations of rheumatic diseases in children
48. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis
49. Hydroxyurea-induced dermatomyositis-like eruption
50. Intravenous pulse methylprednisolone treatment of juvenile dermatomyositis
51. Methotrexare in the treatment of juvenile rheumatoid arthritis and other pediatric rheumatoid and non-rheumatic disorders
52. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis
53. Prednisone and azathioprine for polymyositis: Long-term follow up
54. Preliminary evidence for cyclosporine A as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis
55. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis
56. Intravenous immunoglobulins as treatment of life threatening esophageal involvement on polymyositis an dermatomyositis
57. Treatment of calcinosis with diltiazem
58. Regression of calcinosis during diltiazem treatment in juvenile dermatomyositis
59. A case of calcinosis universalis successfully treated with low-dose warfarin
60. Cutaneous lesions of dermatomyositis are improve dby hydroxychloroquine
61. Low-dose methotrexate administered weekly is an effective corticosteroid-sparing agent for the treatment of the cutaneous manifestations of dermatomyositis
62. Mycophenalate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases
63. Adult onset polymyositis/dermatomyositis: An analysis of clinical and laboratory features and survival in 76 patients with a review of the literature
64. Long-term prognosis of 69 patients with dermatomyositis or polymyositis